Scarica l'app Stockscreener
8.63
1.89%
0.16
Dopo l'orario di chiusura:
8.50
-0.13
-1.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AVXL Giù?
Forum
Previsione
Frazionamento azionario
Anavex Life Sciences Corporation Borsa (AVXL) Ultime notizie
Anavex Life Sciences (NASDAQ:AVXL) vs. Aligos Therapeutics (NASDAQ:ALGS) Head to Head Analysis - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 8.5%Time to Buy? - MarketBeat
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 - The Manila Times
Anavex Life Sciences Sets Date for Q4 2024 Earnings Release and Strategic Update - StockTitan
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap Up – Should You Buy? - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap UpShould You Buy? - MarketBeat
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference - The Manila Times
Anavex to Unveil 4-Year Alzheimer's Drug Data at JPM Healthcare Conference - StockTitan
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 7.8% – Here’s What Happened - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 7.8%What's Next? - MarketBeat
Anavex Life Sciences (LTS:0HFR) EPS (Diluted) : $-0.51 (TTM As of Jun. 2024) - GuruFocus.com
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 - The Manila Times
Anavex Life Sciences to Present at Major Evercore ISI Healthcare Conference - StockTitan
Anavex Life Sciences (NASDAQ:AVXL) Trading 8.1% HigherShould You Buy? - MarketBeat
Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN
Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from HC Wainwright - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Earns “Buy” Rating from D. Boral Capital - Defense World
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA - The Manila Times
Anavex Submits Breakthrough Oral Alzheimer's Drug to European Regulators | AVXL Stock News - StockTitan
Anavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal - The Manila Times
Anavex Life Sciences (NASDAQ:AVXL) Shares Down 4.1%Time to Sell? - MarketBeat
Nwam LLC Purchases New Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by GSA Capital Partners LLP - MarketBeat
Contrasting Palisade Bio (NASDAQ:PALI) & Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Reaches New 52-Week HighShould You Buy? - MarketBeat
Insider Bets Paying Off At AVXL As New 52-Week High Reached - Nasdaq
Anavex Life Sciences (NASDAQ:AVXL) Shares Up 8.1%Here's Why - MarketBeat
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla? - Benzinga
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario - Seeking Alpha
Anavex: Understanding Their Latest Alzheimer's Data News With Caution (NASDAQ:AVXL) - Seeking Alpha
HC Wainwright Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected To Breakeven In The Medium-Term - Simply Wall St
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 - The Manila Times
NY Biopharma Shares Promising Clinical Data - Streetwise Reports
Anavex Life Sciences (NASDAQ:AVXL) Rating Reiterated by HC Wainwright - MarketBeat
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - StockTitan
Anavex reports positive EEG results in schizophrenia trial - Investing.com
Short Interest in Anavex Life Sciences Corp. (NASDAQ:AVXL) Declines By 10.3% - MarketBeat
Examining Anavex Life Sciences Corporation (AVXL) stock is warranted - US Post News
Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Market Insights: Anavex Life Sciences Corporation (AVXL)’s Notable Drop of -2.42, Closing at 5.24 - The Dwinnex
Understanding the Risks of Investing in Anavex Life Sciences Corporation (AVXL) - Knox Daily
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade) (NASDAQ:AVXL) - Seeking Alpha
The time has not yet come to remove your chips from the table: Anavex Life Sciences Corporation (AVXL) - SETE News
Renaissance Technologies LLC Has $1.97 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat
A stock that deserves closer examination: Anavex Life Sciences Corporation (AVXL) - US Post News
Anavex Life Sciences Corporation (AVXL) may enjoy gains as insiders got busy in the recent days - Knox Daily
Anavex Life Sciences Corporation [AVXL] Director makes an insider acquire of 2,835 shares worth 10,319. - Knox Daily
Australian Vanadium gets interest for $31 million finance support - Mining.com.au
AVXL Shares Experience Surge in Value - Knox Daily
Anavex Life Sciences Corp. (NASDAQ:AVXL): Is Breakeven Near? - Yahoo Finance
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):